

Mini-Review

Ionotropic Glutamate Receptors: Regulation by G-protein Coupled Receptors

Asheebo Rojas and Raymond Dingledine

Department of Pharmacology, Emory University, 1510 Clifton Road NE

Atlanta, GA 30322

Running title: GPCR - iGluR Cross-talk

Correspondence to: Raymond Dingledine, PhD
Department of Pharmacology
Emory University School of Medicine
Atlanta, GA 30322
Phone: 404-727-5982
Fax: 404-727-0365
E-mail: rdingledine@pharm.emory.edu

Number of text pages: 27

Number of figures: 2

Number of words:

Abstract	222
Introduction	297
Conclusion	262

Number of references: 53

ABBREVIATIONS:

GluN, NMDA receptor subunit; GluA, AMPA receptor subunit; GluK, kainate receptor subunit; mGlu, metabotropic glutamate receptor; mACh, muscarinic acetylcholine receptor; PKC, protein kinase C; PKA, protein kinase A; SFK, Src family kinase; CaMKII, calcium/calmodulin dependent protein kinase; GPCR, G-protein coupled receptor; iGlu, ionotropic glutamate receptor; GIRK, G-protein regulated inward rectifier K⁺; LTP, long-term potentiation; LTD, long-term depression; SNAP-25, synaptosomal-associated protein 25; PICK1, protein interacting with C kinase 1; GRIP1, glutamate receptor-interacting protein 1; PSD, post synaptic density; PTP, protein tyrosine phosphatase; MAGUK, membrane-associated guanylate kinase; AKAP, A-kinase anchoring protein; Neto, neuropilin tolloid-like protein; PACAP, pituitary adenylate cyclase-activating peptide; RACK1, receptor for activated C kinase 1; SH2, Src homology 2.

Abstract

The function of many ion channels is under dynamic control by coincident activation of G protein – coupled receptors (GPCRs), particularly those coupled to the $G_{\alpha s}$ and $G_{\alpha q}$ family members. Such regulation is typically dependent upon the subunit composition of the ionotropic receptor or channel as well as the GPCR subtype and the cell-specific panoply of signaling pathways available. Because GPCRs and ion channels are so highly represented among targets of FDA-approved drugs, functional cross-talk between these drug target classes is likely to underlie many therapeutic and adverse effects of marketed drugs. GPCRs engage a myriad of signaling pathways that involve protein kinases A and C and, through PKC and interaction with β -arrestin, src kinase and hence the MAP kinase cascades. We focus here on the control of ionotropic glutamate receptor function by GPCR signaling because this form of regulation can influence the strength of synaptic plasticity. The amino acid residues phosphorylated by specific kinases have been securely identified in many ionotropic glutamate receptor subunits, but which of these sites are GPCR targets is less well known even when the kinase has been identified. NMDA, AMPA and heteromeric kainate receptors are all downstream targets of GPCR signaling pathways. The details of GPCR-iGluR cross-talk should inform a better understanding of how synaptic transmission is regulated and lead to new therapeutic strategies for neuropsychiatric disorders.

Introduction

Over 40% of FDA-approved drugs target either G-protein coupled receptors (GPCR) or ion channels (Overington et al., 2006). Interestingly, these two classes of drug target often regulate one another by direct physical interaction or through activation of signaling pathways. Signaling pathways underlying regulation take many forms including activation of ser/thr or tyrosine kinase cascades by G-protein subunits or β -arrestin, with effector mechanisms involving changes in protein-protein interactions that anchor receptors to synaptic scaffolding complexes, changes in channel gating or surface trafficking. Adding further nuance to this form of receptor cross-talk, the agonist affinity for mGlu1 is voltage-dependent due to a gating charge-driven conformational change in the receptor (Ben-Chaim et al., 2006). Thus the ability of mGlu1 receptors to modulate voltage-dependent channels such as NMDA receptors will itself be voltage-dependent. The combination of phospho-specific antibodies, site-directed mutagenesis and functional analysis has allowed the secure identification of dynamically regulated phosphorylation sites on many of the ionotropic glutamate receptor subunits. However, convincing linkage of a specific GPCR to one or more specific phosphorylated amino acids that regulate ionotropic receptor function is uncommon. Several key questions remain for control of glutamate receptor function by GPCRs: Which iGlu receptors are regulated by GPCRs, and in what cell types? Does the regulation occur directly (i.e. physical interaction of the GPCR with regulatory/accessory and scaffolding proteins) or indirectly via intracellular signaling molecules? If the latter, which pathways are involved and which of the potential consensus phosphorylation sites on iGluR are actually utilized? How does cross-talk alter receptor and synaptic function? Here we review the regulation of ionotropic glutamate

receptors (AMPA, NMDA and kainate) by GPCRs with special attention on $G_{\alpha q}$ -coupled mGlu and mACh receptors as these GPCRs are critically involved in synaptic transmission and plasticity and their altered regulation has significant implications in neuropathies.

Ionotropic glutamate receptors

Ionotropic glutamate receptors are classified functionally and by molecular homology into three receptor classes: NMDA (consisting of the GluN1, GluN2A, GluN2B, GluN2C, GluN2D, GluN3A and GluN3B subunits), AMPA (GluA1, GluA2, GluA3, GluA4), and kainate (GluK1, GluK2, GluK3, GluK4, GluK5). Ionotropic glutamate receptors are tetrameric assemblies of multiple subunits. Subunit assembly appears exclusive within a receptor class, for example none of the four AMPA receptor subunits has been shown to coassemble with NMDA receptor subunits to form a functional receptor. We will consider cross-talk regulation of each ionotropic receptor class in turn.

NMDA Receptor Modulation

The regulation of NMDA receptor currents can occur through phosphorylation of regulatory sites located within the GluN1 or GluN2 subunits or via protein-protein interactions, in which changes in the binding of proteins like PSD-95 or calmodulin help to cluster NMDARs at postsynaptic sites. The distal C-terminus of GluN2 subunits contains PDZ motifs that non-covalently link NMDA receptors to scaffolding proteins like those in the PSD-95 family and its associated proteins – MAGUKs and AKAPs. All four GluN2 subunits appear to interact with all four PSD-95 proteins (PSD-95, PSD-93, SAP102, SAP97) typically resulting in a change in surface targeting of NMDA receptors (Bard and Groc, 2011). Over the past two decades attention has also focused on the indirect regulation of NMDARs mediated by the activation of

various GPCRs and their downstream signaling molecules. Figure 1A illustrates several prominent signaling pathways by which GPCRs regulate the channel properties or, more often, surface trafficking, of iGlu receptors.

In addition to receptor cross-talk mediated via diffusible signaling molecules (described below), the C-terminus of the GluN1 subunit has been shown to physically interact with, or reside within the same tight protein complex as, mu opioid receptors (MOR) (Rodriguez-Munoz et al., 2012), D1 dopamine receptors (Lee et al., 2002) and mGlu5a receptors (Perroy et al., 2008). The physical interaction between GluN1 and mGlu5a results in constitutive, agonist-insensitive inhibition of NMDAR, whereas a D1 dopamine receptor agonist both reduces NMDAR currents and weakens the physical interaction between D1 and NMDAR through a PKA/PKC-independent mechanism. By contrast, the MOR – GluN1 interaction could be disrupted by morphine in a PKC-dependent manner. Interestingly, tolerance to morphine can be prevented by PKC inhibitors (Hull et al., 2010), raising the possibility that the MOR-GluN1 physical interaction is somehow required to maintain chronic sensitivity to morphine.

Regulation of NMDARs by mGlu and mACh receptors

Metabotropic glutamate receptors modulate neuronal excitability via regulation of voltage-sensitive calcium channels, GIRK channels, GABA_A receptors, AMPA receptors and NMDA receptors (Conn and Pin, 1997). Eight mGlu receptors are classified into three groups according to their G_α-protein. Group I mGlu receptors (mGlu1 and mGlu5) are coupled to G_{αq} family members and activate the phospholipase C pathway, which leads to an increase in diacylglycerol and IP₃ levels, intracellular calcium, and stimulation of protein kinase C (PKC)

(Figure 1A). An important consequence of group I mGlu activation is modulation of glutamatergic transmission, for example potentiated NMDAR responses in the hippocampus, cerebellum, cortex and spinal cord (Bordi and Ugolini, 1999). Activation of group I mGlu receptors in striatal neurons increases GluN1 phosphorylation at serines 896 and 897 in vivo. The GluN1 phosphorylation was attenuated in the presence of an mGlu5 antagonist suggesting that the phosphorylation is mGlu5 mediated (Choe et al., 2006). The kinase(s) responsible for the phosphorylation was not identified in this study. However, functional cross-talk was observed in HEK293 cells expressing NMDARs containing the GluN2A and GluN2B subunits as well as the mGlu1 receptor where activation of mGlu1 resulted in increased phosphorylation of GluN2A and GluN2B by a Src family tyrosine kinase (Heidinger et al., 2002), suggestive of a β -arrestin or PKC pathway involvement. Although mGlu1 and mGlu5 are both coupled to $G_{\alpha q}$ and they both can potentiate NMDA receptor currents in CA3 pyramidal cells, they appear to do so via two distinct signaling pathways, mGlu1 via a G-protein independent src kinase pathway possibly involving β -arrestin, and mGlu5 via a $G_{\alpha q}$ -PKC-PYK2-src pathway (Benquet et al., 2002).

Neuronal excitability and synaptic transmission are also altered by interactions between the cholinergic and glutamatergic neurotransmitter systems. One mechanism involves potentiation of NMDA receptor currents by M1 muscarinic receptors, which co-localize with the GluN1 subunit in hippocampal CA1 pyramidal cells (Marino et al., 1998). Potentiation of NMDA receptors by M1 AChR activation is mediated by src kinase and postulated to involve a kinase cascade in which PKC phosphorylates PYK2, which in turn phosphorylates and activates src kinase (Lu et al., 1999). The molecular target of src might be three tyrosines on

the C-terminus of GluN2A (Zheng et al., 1998). Thus M1 mAChR and mGlu5 appear to share an identical signaling pathway.

The examples discussed above involve potentiation of NMDA receptor activity, however, there is also evidence for inhibition of NMDA receptor currents following activation of several GPCRs. For example, activation of group I mGlu receptors potentiated NMDA receptor currents in CA1 pyramidal cells, but inhibited NMDA receptor currents in nearby hippocampal CA3 pyramidal cells through a Ca^{2+} dependent mechanism (Grishin et al., 2004), pointing to cell-specific regulation of NMDA receptors by mGlu receptors. Activation of mGlu7 is reported to inhibit NMDAR currents in neurons of the prefrontal cortex by engaging a β -arrestin / ERK pathway, which regulates NMDAR surface trafficking by controlling the polymerization state of actin (Gu et al., 2012). A similar pattern of regulation of NMDA receptors was observed following M1 mAChR activation, in that NMDA receptor responses were potentiated in hippocampal CA1 pyramidal cells but inhibited in hippocampal CA3 pyramidal cells by a mechanism proposed to involve a calmodulin-activated tyrosine phosphatase (Grishin et al., 2005). More complicated signaling pathways also exist. For example, activation of the Gi/Go-coupled 5HT1A receptor on cortical pyramidal neurons suppresses NMDAR currents by destabilizing microtubules leading to reduced NMDAR transport to dendritic membranes. This effect of 5HT1A is countermanded by activation of Gq-coupled 5HT2A, which through a β -arrestin – src – ERK pathway, stabilizes microtubules (Yuen et al., 2008). The overall outcome on NMDA receptor activity, whether potentiated or inhibited, thus depends on the cell population that expresses the receptors, the GPCR subtypes expressed and the many scaffolding and intracellular signaling molecules brought

into play in multiple signaling cascades.

Signaling pathways and NMDAR phosphorylation

NMDA receptors are known to form stable complexes with intracellular cell signaling proteins such as src family kinases (SFKs), calmodulin and G-proteins, which can alter the function and/or distribution of NMDAR subunits. A sequence scan of the intracellular domains of the NMDA receptor subunits reveals consensus phosphorylation sites for both PKA and PKC (Figure 1B) and the phosphorylation of NMDA receptors by these kinases leads to three functional outcomes depending on NMDAR subunit and phosphorylated residues, namely facilitation of NMDA receptor currents via increased channel opening, increased NMDAR surface expression, and suppression of NMDA mediated currents (Chen and Roche, 2007; Traynelis et al., 2010). In addition to PKA and PKC, the calcium/calmodulin dependent protein kinase (CaMKII), and the tyrosine kinases Src and fyn also phosphorylate NMDA receptors (Chen and Roche, 2007; Traynelis et al., 2010). The activation of phosphatases (serine/threonine and tyrosine) leads to dephosphorylation of NMDARs and reduced NMDAR activity (e.g., Grishin et al., 2005), suggesting that the set point of NMDAR responsiveness relies on the balance of intracellular kinase and phosphatase activities.

A prominent mechanism by which GPCR activation alters NMDA receptor activity is by altering the surface expression of NMDA receptor subunits. For example, stimulation of mGlu5 in neurons increases the surface expression of NMDA receptors in a tyrosine kinase dependent manner (Lan et al., 2001). It is now well established that NMDA receptors are involved in elaborate protein-protein interactions with regulatory and accessory proteins at the

post-synaptic density. Non-receptor protein tyrosine kinases such as Src family kinases are critically involved in these interactions. Tyrosine kinases like Pyk2 and Fyn are intertwined in scaffolding complexes that bind to NMDA receptors and alter NMDA function (MacDonald et al., 2007). Models have been developed describing how this regulation may occur. For example, Pyk2 provides an SH2 (Src homology 2) docking site for Src that is normally anchored to NMDA receptors by the protein ND2. Following activation of a $G_{\alpha q}$ coupled GPCR like the M1 or mGlu5 receptors, PKC is activated leading to phosphorylation of Pyk2 that in turn activates Src kinase, which targets a tyrosine near the GluN2B C-terminus and enhances NMDA receptor activity by increasing trafficking to the surface membrane (MacDonald et al., 2007). NMDAR-dependent long-term potentiation at CA1 synapses requires both PYK2 and src (Huang et al., 2001), which emphasizes the importance of this pathway.

GPCR regulation of NMDA receptors is not limited to $G_{\alpha q}$ coupled receptors as $G_{\alpha s}$ coupled GPCRs also play a role, although some key players are different. For example, the GluN2B subunit interacts with an inhibitory scaffolding protein named RACK1. Activation of a $G_{\alpha s}$ coupled GPCR by the PACAP peptide enhanced NMDA receptor function via RACK1 in CA1 hippocampal slices (Yaka et al., 2003). The proposed mechanism involves PKA activation that leads to the dissociation of RACK1 from the NMDA receptor, resulting in translocation of RACK1 to the nucleus and exposure of the C-terminus of GluN2B to Fyn kinase, which phosphorylates GluN2B on Y1474 thereby enhancing NMDA receptor activity (Yaka et al., 2003). MacDonald et al. (2005) reported that NMDA receptor modulation in CA1 neurons by PACAP is dominantly mediated by activation of PKC and Src, rather than the PKA pathway. The multiple pathways by which PACAP regulates NMDA receptors in hippocampal

CA1 neurons deserve further study. In striatal neurons activation of the $G_{\alpha s}$ -coupled dopamine receptor DRD1 leads to the rapid increase in synaptic surface expression of NMDA receptor subunits in a tyrosine phosphorylation dependent manner (Hallett et al., 2006). A model was proposed recently in which dopamine receptor (D1) mediated potentiation of NMDA receptors occurs via phosphorylation of GluN2B subunits by Fyn kinase (Yang et al., 2012). These examples demonstrate that both PKA and PKC downstream of $G_{\alpha s}$ and $G_{\alpha q}$ activation, respectively regulate NMDA receptors through SFKs.

GluN2C subunits in the cerebellum can be phosphorylated by AKT on S1096, which controls their interaction with 14-3-3 ϵ , in turn regulating their surface expression (Chen and Roche, 2009). AKT is itself activated by insulin-like growth factor 1 via β -arrestin and G-protein receptor kinases (Zheng et al., 2012), although the native G-protein coupled receptor hasn't yet been identified.

The GluN1 subunit, present in all functional NMDA receptors, is phosphorylated by PKC at serines 890 and 896 with phosphorylation of S890 resulting in the disruption of GluN1 clustering (Traynelis et al., 2010). The phosphorylation of S896 by PKC does not appear to be important for GluN1 clustering. Interestingly the dual phosphorylation of S896 and S897 by PKC and PKA, respectively, promotes exit of this subunit from the ER resulting in increased surface expression of GluN1 (Chen and Roche, 2007). Both GluN2A and GluN2B are also phosphorylated by PKC. The phosphorylation of GluN2A at S1416 by PKC weakens the binding of CaMKII to the GluN2A subunit, which creates a hierarchy between the PKC and CaMKII signaling pathways (Gardoni et al., 2001). Mutagenesis studies suggest that

phosphorylation of S1303 and S1323 in GluN2B is one route to potentiation by PKC of NMDA receptors containing GluN2B (Chen and Roche, 2007). Both the synaptic GluN2A and the extrasynaptic GluN2B subunits are regulated by the PKC, PKA and the tyrosine kinase Src (Chen and Roche, 2007). The GluN2C receptor contains a common phosphorylation site for both PKA and PKC (S1244) that is located in the PDZ binding motif of the subunit (Figure 1B) and may play a physiological role in cerebellar granule cells where the majority of GluN2C receptors are expressed.

AMPA Receptors

A second subgroup of ionotropic glutamate receptors comprises the α -amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) receptors. These receptors activate and desensitize rapidly in response to glutamate thus mediating rapid excitatory synaptic transmission. An important consequence of AMPA receptor regulation by GPCRs is control of the strength and direction of synaptic plasticity. AMPA receptors are involved in protein-protein interactions with scaffolding proteins such as PICK1, GRIP1 and the more recently discovered TARP accessory proteins such as stargazin, which aid in the trafficking of AMPA receptors and present additional targets for regulation.

mGlu and mACh receptor regulation of AMPARs

Muscarinic receptors (mainly M1) and mGlu receptors induce LTD in the hippocampus and cerebellum mainly through changes in AMPA receptor trafficking (Dickinson et al., 2009; Nomura et al., 2012). Nomura et al. (2012) proposed that cerebellar LTD is mediated by mGlu1 activation and subsequent PKC activation leading to phosphorylation of GluA2, which

causes it to dissociate from GRIP1, diffuse laterally to the endocytic zone and undergo TARP mediated endocytosis. The mACh receptor induced LTD in the hippocampus involves the same signaling mechanism (Dickinson et al., 2009). By contrast, mGlu1 mediated LTD on glutamatergic afferents to dopamine neurons in the ventral tegmental area proceeds by PICK1-dependent selective insertion of perisynaptic GluA2 subunits into synaptic receptors (Bellone and Luscher, 2006), which should reduce channel conductance. Thus cell-specific differences in the signaling pathways and interacting proteins result in specificity of the GPCR mediated AMPA receptor regulation.

AMPA phosphorylation

Accumulating evidence indicates that AMPA receptor activity is regulated by direct phosphorylation of AMPA receptor subunits by PKA and PKC. Although the C-termini of AMPA receptor subunits varies in homology, they all contain consensus phosphorylation sites for serine/threonine kinases (Figure 1A). GluA1, the most well characterized AMPA receptor subunit, is phosphorylated at serine 831 by both PKC and CaMKII whereas a nearby serine (S845) is phosphorylated by PKA. The phosphorylation of S845 by PKA increases the open probability of GluA1 channels (Banke et al., 2000) suggesting enhanced AMPA receptor function. However, the phosphorylation of S845 is also a critical step in LTD that involves delocalization of AMPAR from synaptic regions into perisynaptic sites (Lee et al., 2010), suggesting that trafficking overrides the effect on channel properties. This perisynaptic pool of GluA1 is then available for rapid reuptake into synaptic receptors during LTP. One mechanism for synaptic insertion involves phosphorylation of the GluA1 accessory protein stargazin by CAMKII, which facilitates induction of LTP in hippocampal slices by allowing AMPAR to bind

PSD95 (Tomita et al., 2005) and become sequestered into the synapse.

A large majority of AMPA receptors in the brain contains the GluA2 subunit, which can also be phosphorylated at multiple sites (Figure 1B). PKA phosphorylates GluA2 at S880, which is in the PDZ binding domain of the C-terminus and regulates the interaction of GluA2 with membrane scaffolding proteins such as the glutamate receptor interacting protein-1 (GRIP1) (Matsuda et al., 1999; Chung et al., 2000). Interestingly, GluA4 is phosphorylated by PKA, PKC, and CaMKII at the same C-terminal regulatory site (i.e. S842); phosphorylation of this serine is necessary to remove the ER retention signal and drive trafficking of GluA4 containing receptors to the synapse (Carvalho et al., 1999). An important issue in GluA4 regulation is whether phosphorylation of this site by one kinase alters the sensitivity of the receptor for the binding of other kinases.

Kainate Receptors

Of the three ionotropic glutamate receptor subgroups the synaptic functions of kainate receptors (KARs) are the least well understood. The GluK1-GluK3 subunits have low glutamate affinity and are capable of forming functional homomeric channels. GluK4 and GluK5 are high affinity KAR subunits that bind glutamate, but require co-assembly with one or more GluK1 - GluK3 subunits to form functional channels. The heteromultimeric assembly of KARs like many other ion channels leads to the formation of receptors with unique pharmacological and functional properties. KAR subunits are distributed throughout the nervous system including the hippocampus, cortex, amygdala, striatum, hypothalamus, cerebellum, spinal cord, and basal ganglia where they are involved in synaptic transmission

and plasticity (Jin and Smith, 2011). KAR are regulated by several GPCR pathways previously thought to affect only NMDA and AMPA receptors.

mGlu receptor regulation of KARs

One of the earliest demonstrations of regulation of KARs by mGlu receptors was carried out by Cho et al. (2003), who showed that mGlu5 receptor activation potentiates ATPA activated kainate currents on neurons in the perirhinal cortex. In this study KAR potentiation occurred in the presence of cyclopiazonic acid, which depletes calcium stores and inhibits the mGlu5-dependent increase in internal calcium. The potentiation was blocked by pharmacological inhibitors of PKC, however it remained unclear whether PKC activation was necessary and sufficient to potentiate KAR responses. It was also not clear which subunits of KAR were involved in the modulation. Rojas et al. (2012) recently demonstrated the regulation of heteromeric KARs by group I mGlu receptors in cultured cortical and hippocampal neurons and *Xenopus* oocytes. Pronounced potentiation of heteromeric KAR (consisting of high and low affinity subunits) currents was observed following activation of group I mGlu receptors (Figure 2A,B). On the other hand, homomeric KARs expressed in *Xenopus* oocytes failed to be potentiated following group I mGlu receptor activation. The potentiation pathway involved phospholipase C, Ca²⁺ mobilization, and PKC as potentiation was blocked by inhibitors of all three signaling molecules. There was an interesting difference between the findings by Rojas et al. (2012) and Cho et al. (2003), namely the involvement of Ca²⁺ mobilization in the regulation of KARs by group I mGlu receptors. In the Cho et al. (2003) study the mGlu5 mediated potentiation of ATPA activated KAR currents was calcium independent, however in the Rojas et al. (2012) the potentiation of heteromeric KARs by activation of group I mGlu

receptors was clearly calcium dependent as the potentiation was lost in the presence of the calcium chelator BAPTA. This difference in the contribution of a critical signaling molecule suggests that there may be multiple pathways regulating KARs following mGlu receptor activation.

mACh receptor regulation of KARs

Benveniste et al. (2010) demonstrated that activation of GluK2 containing heteromeric kainate receptors is potentiated following mACh receptor activation. Similar to mGlu receptor modulation of KARs, muscarinic receptor (M1 and M3) activation by pilocarpine potentiated GluK2 containing heteromeric, but not homomeric KARs, suggesting that potentiation of KARs by mACh receptors also requires the high affinity KAR subunits. The regulation was also observed in mossy fibers using the hippocampal slice preparation, where mACh mediated potentiation seen in native neurons displayed similar characteristics as that seen with recombinant receptors, such as the degree of potentiation, the time-dependence, and the specificity for mACh receptor agonists. The mechanism responsible for mACh receptor potentiation was not investigated.

KAR phosphorylation

A sequence scan of the C-terminus of KAR subunits reveals a number of consensus phosphorylation sites for the protein kinases PKC, PKA, CaMKII, and Src. PKC phosphorylates the C-terminus of both GluK1 and GluK2 in vitro (Chamberlain et al., 2012; Hirbec et al., 2003; Konopacki et al., 2011; Nasu-Nishimura et al., 2010). The phosphorylation of GluK2 by PKC at S868 is a critical step in the process of internalization of GluK2 that occurs

during KAR mediated LTP in hippocampal mossy fibers (Chamberlain et al., 2012). On the other hand phosphorylation of C-terminal residues (i.e. S880 and S886) in GluK1 appears to promote the stability of this subunit in the synapse via an interaction with the PDZ-domain containing protein GRIP1 (Hirbec et al., 2003). The C-terminus of GluK2 is also phosphorylated by PKA at S825 and S837 (Kornreich et al., 2007) leading to potentiation of receptor currents likely via an increase in the receptor open-probability. Site-directed mutagenesis led to the identification of three serines in the GluK5 subunit that are responsible for PKC-mediated potentiation of KAR by group I mGlu receptors (Fig 2C,D; Rojas et al., 2012). Selak et al. (2009) reported reduced GluK5 expression via PKC-mediated disruption of the interaction of GluK5 with the synaptic proteins SNAP-25 and PICK1. The authors suggested that PKC interacts with PICK1 resulting in the disruption of the SNAP-25-PICK1-GluK5 complex. These examples show that, as for NMDAR and AMPAR, KAR functions can be both potentiated and suppressed by PKC.

Conclusion and Outlook

The mechanisms responsible for regulation of iGlu receptors by GPCRs involve many intracellular signaling molecules and regulatory proteins that vary from one cell type to another. The downstream signaling molecules include protein kinases that phosphorylate regulatory sites located within the C-terminus of these ionotropic glutamate receptors affecting their interaction with regulatory or interacting proteins that alter iGlu receptor trafficking (Figure 1A). In some cases synaptic regulation of ionotropic glutamate receptors by the activation of diverse GPCRs proceeds by partially convergent mechanisms shared by the various iGlu receptors, exemplified by the convergence of muscarinic and metabotropic glutamate

receptors onto PKC pathways that regulate all three iGlu receptors, albeit via different mechanisms downstream of PKC. Knowing that ionotropic glutamate receptors are subject to many of the same modulatory influences has implications for understanding the physiological roles of these receptors in concert. One important issue is to understand whether cross-talk is restricted to cellular compartments that co-express ionotropic glutamate receptors and GPCRs. Second, knowledge of the molecular basis of kinase specificity of cross-talk mediated by multiple GPCRs and whether there is a dominance hierarchy of kinases and hence to ion channel modulation will result in better understanding of how synaptic strength is regulated. It will also be important to identify the conditions under which changes in channel conductance play a role in synaptic strength modification by GPCRs, given the dominant role of receptor trafficking in this process. Finally, the therapeutic implications of cross-talk between NMDAR and dopamine D1 receptors (e.g., for schizophrenia), mu opioid receptors (for chronic pain) and mGlu5a (for cognitive disorders) are considerable.

AUTHORSHIP CONTRIBUTIONS

Wrote or contributed to the writing of the manuscript: Rojas and Dingledine

References

- Banke TG, Bowie D, Lee H, Huganir RL, Schousboe A, Traynelis SF. (2000) Control of GluR1 AMPA receptor function by cAMP-dependent protein kinase. *J Neurosci.* 20: 89-102.
- Bard L and Groc L (2011) Glutamate receptor dynamics and protein interaction: lessons from the NMDA receptor. *Molecular and cellular neurosciences* **48**(4):298-307.
- Bellone C and Luscher C (2006) Cocaine triggered AMPA receptor redistribution is reversed in vivo by mGluR-dependent long-term depression. *Nature neuroscience* **9**(5):636-641.
- Ben-Chaim Y, Chanda B, Dascal N, Bezanilla F, Parnas I and Parnas H (2006) Movement of 'gating charge' is coupled to ligand binding in a G-protein-coupled receptor. *Nature* **444**(7115):106-109.
- Benquet P, Gee CE and Gerber U (2002) Two distinct signaling pathways upregulate NMDA receptor responses via two distinct metabotropic glutamate receptor subtypes. *The Journal of neuroscience* **22**(22):9679-9686.
- Benveniste M, Wilhelm J, Dingledine RJ and Mott DD (2010) Subunit-dependent modulation of kainate receptors by muscarinic acetylcholine receptors. *Brain research* **1352**:61-69.
- Carvalho AL, Kameyama K and Huganir RL (1999) Characterization of phosphorylation sites on the glutamate receptor 4 subunit of the AMPA receptors. *The Journal of neuroscience* : **19**(12):4748-4754.
- Chamberlain SE, Gonzalez-Gonzalez IM, Wilkinson KA, Konopacki FA, Kantamneni S, Henley JM and Mellor JR (2012) SUMOylation and phosphorylation of GluK2 regulate kainate receptor trafficking and synaptic plasticity. *Nature neuroscience* **15**(6):845-852.
- Chen BS and Roche KW (2007) Regulation of NMDA receptors by phosphorylation.

Neuropharmacology **53**(3):362-368.

- Chen BS, Roche KW. (2009) Growth factor-dependent trafficking of cerebellar NMDA receptors via protein kinase B/Akt phosphorylation of NR2C. *Neuron*. 62: 471-478.
- Cho K, Francis JC, Hirbec H, Dev K, Brown MW, Henley JM and Bashir ZI (2003) Regulation of kainate receptors by protein kinase C and metabotropic glutamate receptors. *The Journal of physiology* **548**(Pt 3):723-730.
- Choe ES, Shin EH and Wang JQ (2006) Regulation of phosphorylation of NMDA receptor NR1 subunits in the rat neostriatum by group I metabotropic glutamate receptors in vivo. *Neuroscience letters* **394**(3):246-251.
- Chung HJ, Xia J, Scannevin RH, Zhang X and Huganir RL (2000) Phosphorylation of the AMPA receptor subunit GluR2 differentially regulates its interaction with PDZ domain-containing proteins. *The Journal of neuroscience* **20**(19):7258-7267.
- Conn PJ and Pin JP (1997) Pharmacology and functions of metabotropic glutamate receptors. *Annual review of pharmacology and toxicology* **37**:205-237.
- Dickinson BA, Jo J, Seok H, Son GH, Whitcomb DJ, Davies CH, Sheng M, Collingridge GL and Cho K (2009) A novel mechanism of hippocampal LTD involving muscarinic receptor-triggered interactions between AMPARs, GRIP and liprin-alpha. *Molecular brain* **2**:18.
- Gardoni F, Bellone C, Cattabeni F, Di Luca M. (2001) Protein kinase C activation modulates alpha-calmodulin kinase II binding to NR2A subunit of N-methyl-D-aspartate receptor complex. *J Biol Chem*. 276: 7609-7613.
- Grishin AA, Benquet P and Gerber U (2005) Muscarinic receptor stimulation reduces NMDA responses in CA3 hippocampal pyramidal cells via Ca²⁺-dependent activation of tyrosine

phosphatase. *Neuropharmacology* **49**(3):328-337.

Grishin AA, Gee CE, Gerber U and Benquet P (2004) Differential calcium-dependent modulation of NMDA currents in CA1 and CA3 hippocampal pyramidal cells. *The Journal of neuroscience* **24**(2):350-355.

Gu Z, Liu W, Wei J, Yan Z. (2012) Regulation of N-methyl-D-aspartic acid (NMDA) receptors by metabotropic glutamate receptor 7. *J Biol Chem.* 287:10265-75.

Hallett PJ, Spoelgen R, Hyman BT, Standaert DG and Dunah AW (2006) Dopamine D1 activation potentiates striatal NMDA receptors by tyrosine phosphorylation-dependent subunit trafficking. *The Journal of neuroscience* **26**(17):4690-4700.

Heidinger V, Manzerra P, Wang XQ, Strasser U, Yu SP, Choi DW and Behrens MM (2002) Metabotropic glutamate receptor 1-induced upregulation of NMDA receptor current: mediation through the Pyk2/Src-family kinase pathway in cortical neurons. *The Journal of neuroscience* **22**(13):5452-5461.

Heinke B, Gingl E and Sandkuhler J (2011) Multiple targets of mu-opioid receptor-mediated presynaptic inhibition at primary afferent Adelta- and C-fibers. *The Journal of neuroscience* **31**(4):1313-1322.

Hirbec H, Francis JC, Lauri SE, Braithwaite SP, Coussen F, Mulle C, Dev KK, Coutinho V, Meyer G, Isaac JT, Collingridge GL and Henley JM (2003) Rapid and differential regulation of AMPA and kainate receptors at hippocampal mossy fibre synapses by PICK1 and GRIP. *Neuron* **37**(4):625-638.

Huang Y, Lu W, Ali DW, Pelkey KA, Pitcher GM, Lu YM, Aoto H, Roder JC, Sasaki T, Salter MW, MacDonald JF (2001). CAKbeta/Pyk2 kinase is a signaling link for induction of long-term potentiation in CA1 hippocampus. *Neuron.* 29:485-96.

- Hull LC, Llorente J, Gabra BH, Smith FL, Kelly E, Bailey C, Henderson G, Dewey WL. (2010) The effect of protein kinase C and G protein-coupled receptor kinase inhibition on tolerance induced by mu-opioid agonists of different efficacy. *J Pharmacol Exp Ther.* 332: 1127-1135.
- Jin XT and Smith Y (2011) Localization and functions of kainate receptors in the basal ganglia. *Advances in experimental medicine and biology* **717**:27-37.
- Konopacki FA, Jaafari N, Rocca DL, Wilkinson KA, Chamberlain S, Rubin P, Kantamneni S, Mellor JR and Henley JM (2011) Agonist-induced PKC phosphorylation regulates GluK2 SUMOylation and kainate receptor endocytosis. *Proceedings of the National Academy of Sciences of the United States of America* **108**(49):19772-19777.
- Kornreich BG, Niu L, Roberson MS, Oswald RE. (2007) Identification of C-terminal domain residues involved in protein kinase A-mediated potentiation of kainate receptor subtype 6. *Neuroscience.* 146: 1158-1168.
- Lan JY, Skeberdis VA, Jover T, Zheng X, Bennett MV and Zukin RS (2001) Activation of metabotropic glutamate receptor 1 accelerates NMDA receptor trafficking. *The Journal of neuroscience* **21**(16):6058-6068.
- Lee FJ, Xue S, Pei L, Vukusic B, Chéry N, Wang Y, Wang YT, Niznik HB, Yu XM, Liu F. (2002) Dual regulation of NMDA receptor functions by direct protein-protein interactions with the dopamine D1 receptor. *Cell.* 111: 219-230.
- Lee HK, Takamiya K, He K, Song L, Huganir RL. (2010) Specific roles of AMPA receptor subunit GluR1 (GluA1) phosphorylation sites in regulating synaptic plasticity in the CA1 region of hippocampus. *J Neurophysiol.* 103: 479-489.
- Leonard AS, Bayer KU, Merrill MA, Lim IA, Shea MA, Schulman H and Hell JW (2002)

Regulation of calcium/calmodulin-dependent protein kinase II docking to N-methyl-D-aspartate receptors by calcium/calmodulin and alpha-actinin. *The Journal of biological chemistry* **277**(50):48441-48448.

Lu WY, Xiong ZG, Lei S, Orser BA, Dudek E, Browning MD and MacDonald JF (1999) G-protein-coupled receptors act via protein kinase C and Src to regulate NMDA receptors. *Nature neuroscience* **2**(4):331-338.

Luscher C and Slesinger PA (2010) Emerging roles for G protein-gated inwardly rectifying potassium (GIRK) channels in health and disease. *Nature reviews Neuroscience* **11**(5):301-315.

Macdonald DS, Weerapura M, Beazely MA, Martin L, Czerwinski W, Roder JC, Orser BA and MacDonald JF (2005) Modulation of NMDA receptors by pituitary adenylate cyclase activating peptide in CA1 neurons requires G alpha q, protein kinase C, and activation of Src. *The Journal of neuroscience* **25**(49):11374-11384.

MacDonald JF, Jackson MF and Beazely MA (2007) G protein-coupled receptors control NMDARs and metaplasticity in the hippocampus. *Biochimica et biophysica acta* **1768**(4):941-951.

Marino MJ, Rouse ST, Levey AI, Potter LT and Conn PJ (1998) Activation of the genetically defined m1 muscarinic receptor potentiates N-methyl-D-aspartate (NMDA) receptor currents in hippocampal pyramidal cells. *Proceedings of the National Academy of Sciences of the United States of America* **95**(19):11465-11470.

Matsuda S, Mikawa S and Hirai H (1999) Phosphorylation of serine-880 in GluR2 by protein kinase C prevents its C terminus from binding with glutamate receptor-interacting protein. *Journal of neurochemistry* **73**(4):1765-1768.

- Nasu-Nishimura Y, Jaffe H, Isaac JT and Roche KW (2010) Differential regulation of kainate receptor trafficking by phosphorylation of distinct sites on GluR6. *The Journal of biological chemistry* **285**(4):2847-2856.
- Nomura T, Kakegawa W, Matsuda S, Kohda K, Nishiyama J, Takahashi T and Yuzaki M (2012) Cerebellar long-term depression requires dephosphorylation of TARP in Purkinje cells. *The European journal of neuroscience* **35**(3):402-410.
- Overington JP, Al-Lazikani B and Hopkins AL (2006) How many drug targets are there? *Nature reviews Drug discovery* **5**(12):993-996.
- Padgett CL and Slesinger PA (2010) GABAB receptor coupling to G-proteins and ion channels. *Advances in pharmacology* **58**:123-147.
- Perroy J, Raynaud F, Homburger V, Rousset MC, Telley L, Bockaert J, Fagni L. (2008) Direct interaction enables cross-talk between ionotropic and group I metabotropic glutamate receptors. *J Biol Chem.* **283**: 6799-6805.
- Rodríguez-Muñoz M, Sánchez-Blázquez P, Vicente-Sánchez A, Berrocoso E, Garzón J. (2012) The mu-opioid receptor and the NMDA receptor associate in PAG neurons: implications in pain control. *Neuropsychopharmacology.* **37**: 338-349.
- Rojas A, Wetherington J, Shaw R, Serrano G, Swanger S and Dingledine R (2012) Activation of Group I Metabotropic Glutamate Receptors Potentiates Heteromeric Kainate Receptors. *Molecular pharmacology.*
- Selak S, Paternain AV, Aller MI, Pico E, Rivera R and Lerma J (2009) A role for SNAP25 in internalization of kainate receptors and synaptic plasticity. *Neuron* **63**(3):357-371.
- Tomita, S., Stein, V., Stocker, T. J., Nicoll, R. A. & Brecht, D. S. (2005) Bidirectional synaptic plasticity regulated by phosphorylation of stargazin-like TARPs. *Neuron* **45**, 269–277.

- Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, Hansen KB, Yuan H, Myers SJ and Dingledine R (2010) Glutamate receptor ion channels: structure, regulation, and function. *Pharmacological reviews* **62**(3):405-496.
- Yaka R, He DY, Phamluong K and Ron D (2003) Pituitary adenylate cyclase-activating polypeptide (PACAP(1-38)) enhances N-methyl-D-aspartate receptor function and brain-derived neurotrophic factor expression via RACK1. *The Journal of biological chemistry* **278**(11):9630-9638.
- Yang K, Trepanier C, Sidhu B, Xie YF, Li H, Lei G, Salter MW, Orser BA, Nakazawa T, Yamamoto T, Jackson MF, Macdonald JF. (2011) Metaplasticity gated through differential regulation of GluN2A versus GluN2B receptors by Src family kinases. *EMBO J.* 31:805-16.
- Yuen EY, Jiang Q, Chen P, Gu Z, Feng J, Yan Z. (2005) Serotonin 5-HT1A receptors regulate NMDA receptor channels through a microtubule-dependent mechanism. *J Neurosci.* 25: 5488-501.
- Zheng F, Gingrich MB, Traynelis SF, Conn PJ. (1998) Tyrosine kinase potentiates NMDA receptor currents by reducing tonic zinc inhibition. *Nat Neurosci.* 1:185-91.
- Zheng H, Worrall C, Shen H, Issad T, Seregard S, Girnita A, Girnita L. (2012) Selective recruitment of G protein-coupled receptor kinases (GRKs) controls signaling of the insulin-like growth factor 1 receptor. *Proc Natl Acad Sci U S A.* 109: 7055-7060.


Figure Legends

Figure 1. Schematic of the regulation of ionotropic glutamate receptors by GPCR

activation. A. Mechanisms, signaling pathways, and molecules underlying the regulation of ionotropic glutamate receptor by $G_{\alpha q}$ -coupled and $G_{\alpha s}$ -coupled GPCR receptor activation. Dashed arrows represent translocation of a signaling molecule, whereas solid arrows represent enzymatic action. Additional pathways mediated by association of GPCR with β -arrestin and subsequent engagement of AKT and ERK pathways are omitted for simplicity. **B.** Phosphorylation of iGlu receptor C-terminal domains. These phosphorylation sites modulate receptor trafficking, channel activity, and protein-protein interactions. The left column contains the receptor subunit name. UniProt-SwissProt human accession numbers were used for each receptor (Traynelis et al., 2010). The beginning and ending amino acid numbers are on the left and right of the C-terminal domain (CTD), respectively. Only a portion of the C-terminal domain is shown for NMDA receptors. Modified residues are colored coded according to the legend.

Figure 2. Potentiation of heteromeric KARs by group I mGlu activation. A, Whole-cell currents were recorded from oocytes expressing GluK2/mGlu1, GluK2/GluK4/mGlu1, or GluK2/GluK5/mGlu1. Following application of 100 μ M ACPD (a non-specific mGlu activator), steady-state activation of the heteromeric receptors by AMPA (30 μ M) was potentiated, but not steady-state activation of the homomeric KAR by domoic acid (10 μ M). **B,** Time-dependent potentiation of GluK2/GluK4/mGlu1 and GluK2/GluK5/mGlu1 AMPA currents by mGlu1

activation with ACPD (n=5 and n=16, respectively). **C**, Schematic showing the GluK5 C-terminal domain. The first red triangle indicates the location of an inserted stop codon ($\Delta 837$) and the second red triangle indicates the position of a more distal stop codon ($\Delta 884$). The red residues indicate consensus PKC phosphorylation sites. **D**, Alanine mutagenesis of the C-terminal serines and threonines between 833 and 883 revealed that only the triple GluK5 mutant (GluK5-S833A/S836A/S840A) resulted in a significantly reduced mGlu1 mediated potentiation (n \geq 4, each mutant combination was evaluated against a separate set of oocytes expressing WT receptors; **** $p < 0.001$; t-test). From Rojas et al. (2012).



B

GluA1	827	EFCYKSR S ESKRMKGFLIPQQ S INEAIR T SLPR N SGAG	866
GluA2	834	EFCYKSRAEAKRMKVAKNAQINNPSSQ S QNFATYKEGV Y YGIES V KI	883
GluA4A	834	EFCYKSRAEAKRMKVAKSAQTFNPTSSQ T QNLATYREGV N YGT E SIKI	883
GluA4B	835	EFCYKSRAEAKRMKLT F SEAIRNKAR L SITGSVGENGRV L TPDCPKAVHTGT A IRQSSGLAVIAS D LP	902
GluK1	841	EFYIKSRK N NDIEQCLFS N AIM E ELGISLKNQK K IKK S RTKG S SFTSILT C HQRRT Q RKET V A	905
GluK2	841	EFLYKSKNAQLE K RS F CSAMVEELR M SLK Q RR L KHK Q PAPV I VKTEEV I NM H TF N DRRL P KG K ET M A	908
GluK5	825	EFIW S TRR S AE S EE V SV C Q E MLQ L R H AV S CR K TSR S RR R RR	866
GluN1	834	E I AY K R H KDARR K Q M LQ A FA V AV N VR K N L QDR K SGRA E PD P KK A T F RA I T S LA S FK R RR S S K DT S TGG G	905
GluN2A	1282	KL R ISR Q HS Y DN I V D K P RE L DL S RP S RS I L K DRER L LE G FN Y GS L F S VP S SK L SG K K S SL P D H T S DN P FL S HR D D Q RL V IG R CP S DP Y K H SL P S Q AV N D S Y L R S SL R ST A S C Y S DR S RG H ND V Y I ES	1426
GluN2B	1280	K Y P Q S P T N S K A Q K N R N K L RR Q H S Y D T F VD L Q E E A AL P RR S V SL K DK G RF M D G SP Y A H M F E M S A G E S T F AN N K S S V P T AG H H H H I N G S S N G H V Y E K L S S I E S D V	1484
GluN2C	1166	PH L PP C A S H G S W L S GA W GL P GR H R T L G L G T G Y R D S GG L DE I S R V A R G T Q G F PG P CT W RR I S S LE S EV	1233
GluD2	928	T T TF I PE Q I T L S RT L S A K A S G F T G N V PE H RT G PF R H R AP N GG F FR S PI K T M S S IP Y Q P T L GL N L G ND P DR G TS I	1007

UniProt-SwissProt (human)

GluA1	P42261
GluA2	P42262
GluA4A	Q1WWWK6
GluA4B	P48058
GluK1	P39086
GluK2	Q13002
GluK5	Q16478
GluN1	Q05586
GluN2A	Q12879
GluN2B	Q13224
GluN2C	Q14957
GluD2	Q43424

Red=PKC site
Blue=PKA site
Green=PKC+PKA site

Figure 1







Figure 2